CTLA4 and colitis: The fecal microbiota of melanoma patients who developed colitis after being treated with ipilimumab, an anti-CTLA-4 immune checkpoint inhibitor, were found to have decreased abundance of Firmicutes at onset of colitis, but enriched Firmicutes at baseline, whereas increased baseline Bacteroidetes was seen in patients who did not develop colitis [50].